Radcliffe Capital Management’s Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share IBER.WS Stock Holding History

Radcliffe Capital Management’s Portfolio IBER.WS Stock Details IBER.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-150,000	Closed	-$1.51M	–	832
2022 Q4	$1.51M	Hold	150,000	–	–	0.05%	565
2022 Q3	$1.49M	Hold	150,000	–	–	0.04%	781
2022 Q2	$1.47M	Hold	150,000	–	–	0.03%	826
2022 Q1	$1.47M	Hold	150,000	–	–	0.03%	808
2021 Q4	$1.46M	Hold	150,000	–	–	0.04%	702
2021 Q3	$1.45M	Hold	150,000	–	–	0.04%	591
2021 Q2	$1.45M	Buy	+150,000	New	+$91.1K	0.05%	616

Other funds holding IBER.WS

LCM

Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return

Radcliffe Capital Management's IBER.WS Position: Q1 2023 in Review

Radcliffe Capital Management sold out of Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) in Q1 2023, closing a stake of 150,000 shares — an estimated $1.51M sold.

Radcliffe Capital Management first reported a position in IBER.WS in Q2 2021 and held it in 7 quarters. The position peaked at $1.51M in Q4 2022. 1 fund tracked by Wall St. Rank holds IBER.WS as of Q1 2023.

Radcliffe Capital Management reported no remaining Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position as of Q1 2023 after selling out during the quarter.
Radcliffe Capital Management sold 150,000 Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share shares in Q1 2023, an estimated $1.51M.
Radcliffe Capital Management first reported a position in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share in Q2 2021 and held it in 7 quarters.
Radcliffe Capital Management's Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position peaked at $1.51M in Q4 2022.
1 fund tracked by Wall St. Rank held Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share as of Q1 2023.

Based on Radcliffe Capital Management's 13F filing for Q1 2023, filed 15 May 2023.